The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

SLL, a subsidiary of the JoongAng Group, said it will start the “Beam” Korea-Taiwan drama co-development project in ...

Over the past decade, InnoCare has achieved remarkable results. 2026 marks the beginning of the Company’s next golden decade of development. Driven by its outstanding performance in 2025, the Company ...

© 2026 Forbes Media LLC. All Rights Reserved.

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...

Police have taped off Huntington Ave. & 53rd St. in Newport News Wednesday morning. The reason remains unclear as officials ...

© 2026 Forbes Media LLC. All Rights Reserved.

Hall of Fame pitcher Mariano Rivera, pictured here saluting the crowd prior to Spring Training Game on March 24, 2024 in ...

Olverembatinib, an investigational multikinase inhibitor (approved in China for CML), inhibits Src-family kinases (e.g., Lyn, ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma ...

Boston-based Kelonia is engaged in the hot area of in vivo CAR-T therapies, presenting encouraging results with its ...

We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. Eli Lilly and Company is among the ...